Multiple Myeloma
Conditions
Interventions
ABCD group:ABCDChemotherapy
Sponsors
Huadong Hospital Affiliated To Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Blood, urine immunofixation electrophoresis, bone marrow examination and cytogenetics, CRAB symptoms, SLiM symptoms, diagnosis of active multiple myeloma under the IMWG standard (symptomatic myeloma); 2) The ECOG score is 0 to 3; 3) Liver function is sound (BUN = 1.5 times the reference value, SGPT = 2 times the reference value); 4) Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraceptive measures during treatment; 5) Subjects must sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1) has been diagnosed as hematological tumor; 2) Those who have participated in other clinical trials within 30 days; 3) pregnant and breast-feeding patients; 4) Have received any treatment for this tumor in the past 3 years, but remove superficial bladder cancer, basal cells or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN) or prostate intraepithelial neoplasia (PIN)); 5) Active viral or bacterial infections that are not controlled by appropriate anti-infective treatment; 6) The serological response of HIV or active hepatitis C virus is known to be positive; 7) suffering from mental illness or other conditions that do not meet the requirements of research treatment and monitoring; 8) bone marrow evacuation; 9) Those who are known to be allergic to any of the ingredients in the protocol; He has received bortezomib or has received a hematopoietic stem cell transplant in the past year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total effectiveness of induction therapy;OS;PFS; | — |
Countries
China
Contacts
Public ContactXie Yanhui
Huadong Hospital Affiliated To Fudan University
Outcome results
None listed